Risk factors for surgical site infection after pancreatic surgery: a better postoperative antibiotic strategy is possible.


Journal

The Journal of hospital infection
ISSN: 1532-2939
Titre abrégé: J Hosp Infect
Pays: England
ID NLM: 8007166

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 25 05 2020
revised: 19 08 2020
accepted: 20 09 2020
pubmed: 28 9 2020
medline: 14 7 2021
entrez: 27 9 2020
Statut: ppublish

Résumé

Pancreatic surgery is associated with high morbidity, mainly due to infectious complications, so many centres use postoperative antibiotics (ATBpo) for all patients. However, antibiotic regimens vary according to local practices. The aims of this study were to describe the occurrence of surgical site infection (SSI) and ATBpo prescription after pancreatic surgery, and to determine the risk factors of postoperative SSI, in order to better define the clinical indications for ATBpo in this context. All patients undergoing scheduled major pancreatic surgery from January 2007 to November 2018 were included in this retrospective study. Patients were classified into four groups according to SSI and routine ATBpo prescription: SSI+/ATBpo+, SSI-/ATBpo+, SSI+/ATBpo- and SSI-/ATBpo-. In addition, risk factors (fever and pre-operative biliary prosthesis) associated with the occurrence of SSI and ATBpo were analysed using a logistic regression model. Data from 149 patients (115 pancreaticoduodenectomies and 34 splenopancreatectomies) were analysed. Thirty (20.1%) patients experienced SSI and 42 (28.2%) received ATBpo. No difference was found in routine ATBpo prescription between patients with and without SSI (26.7% vs 28.6%, respectively; P=0.9). Amongst the 107 patients who did not receive routine ATBpo, 85 (79.4%) did not develop an SSI. In-hospital mortality did not differ between infected and uninfected patients (7% vs 2%, respectively; P=0.13). The occurrence of postoperative fever differed between SSI+ and SSI- patients (73.3% vs 34.2%, respectively; P<0.001), while the prevalence of pre-operative biliary prosthesis was similar (37.9% vs 26.7%, respectively; P=0.3). Non-routine ATBpo after major pancreatic surgery resulted in 85 (56%) patients being spared unnecessary antibiotic treatment. This suggests that routine ATBpo prescription could be excessive, but further studies are needed to confirm such antibiotic stewardship. Fever appears to be a relevant clinical sign for individual-based prescription, but the presence of a biliary prosthesis does not.

Identifiants

pubmed: 32980490
pii: S0195-6701(20)30448-5
doi: 10.1016/j.jhin.2020.09.023
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

28-34

Informations de copyright

Copyright © 2020 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Auteurs

M Petit (M)

Assistance Publique-Hôpitaux de Paris, University Hospital Ambroise Paré, Intensive Care Unit, Section Thorax-Vascular Disease-Abdomen-Metabolism, Boulogne-Billancourt, France.

G Geri (G)

Assistance Publique-Hôpitaux de Paris, University Hospital Ambroise Paré, Intensive Care Unit, Section Thorax-Vascular Disease-Abdomen-Metabolism, Boulogne-Billancourt, France; Paris-Saclay University, Saint-Quentin en Yvelines, France; INSERM, Villejuif, France.

E Salomon (E)

Paris-Saclay University, Saint-Quentin en Yvelines, France; Assistance Publique-Hôpitaux de Paris, University Hospital Ambroise Paré, Microbiology Unit, Section Biology Pathology and Health Products, Boulogne-Billancourt, France.

M Victor (M)

Assistance Publique-Hôpitaux de Paris, University Hospital Ambroise Paré, Hematology-Immunology-Transfusion, Boulogne-Billancourt, France.

F Peschaud (F)

Paris-Saclay University, Saint-Quentin en Yvelines, France; Assistance Publique-Hôpitaux de Paris, University Hospital Ambroise Paré, Digestive Oncological and Metabolic Surgery, Boulogne-Billancourt, France.

A Vieillard-Baron (A)

Assistance Publique-Hôpitaux de Paris, University Hospital Ambroise Paré, Intensive Care Unit, Section Thorax-Vascular Disease-Abdomen-Metabolism, Boulogne-Billancourt, France; Paris-Saclay University, Saint-Quentin en Yvelines, France; INSERM, Villejuif, France.

X Repessé (X)

Assistance Publique-Hôpitaux de Paris, University Hospital Ambroise Paré, Intensive Care Unit, Section Thorax-Vascular Disease-Abdomen-Metabolism, Boulogne-Billancourt, France. Electronic address: xavier.repesse@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH